Synthetic Biologics (NYSEAMERICAN:SYN) released its quarterly earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.07, Morningstar.com reports.
Synthetic Biologics (NYSEAMERICAN:SYN) traded down $0.01 during mid-day trading on Friday, hitting $0.38. 1,028,429 shares of the stock were exchanged, compared to its average volume of 800,520. Synthetic Biologics has a twelve month low of $0.37 and a twelve month high of $1.05. The firm has a market capitalization of $53.64, a P/E ratio of -1.77 and a beta of 1.08.
A number of research firms have recently weighed in on SYN. Zacks Investment Research downgraded shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. BidaskClub downgraded shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th.
ILLEGAL ACTIVITY WARNING: “Synthetic Biologics (SYN) Posts Earnings Results, Beats Expectations By $0.07 EPS” was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/02/23/synthetic-biologics-syn-posts-earnings-results-beats-expectations-by-0-07-eps.html.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.